Brief: Onxeo announces development of Beleodaq Oral formulation

Valerio Therapeutics SA

02/06/2016 17:31

June 2 (Reuters) - Onxeo Sa  C4X.PA  
    * Onxeo announces development of Beleodaq Oral formulation opening new opportunities for its 
HDAC inhibitor 
    * First set of positive results from a preclinical pharmacokinetic (PK) study on 
bioavailability of an oral formulation of belinostat (Beleodaq) 
    * Findings from this study showed a good level of bioavailability approaching theoretical 
maximum achievable as indicated by performance of oral solution 
    * Onxeo will then select best of two formulation technologies 
 
Source text for Eikon:  ID:nBwbjfX6Va  
Further company coverage:  C4X.PA  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 698 3920;))